Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CXFTH
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Serclutamab talirine
|
|||||
| Synonyms |
serclutamab talirine; ABBV-321; Ser-T
Click to Show/Hide
|
|||||
| Organization |
AbbVie (Top20 MNC) (Originator);Life Science Pharmaceuticals (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Serclutamab
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
SGD-1882
|
Payload Info | ||||
| Therapeutic Target |
Human deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mc-Val-Ala
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
| Combination Type |
talirine
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Discovered Using Patient-derived Xenograft Model
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligibility requires ECOG 0-1 patients with progressive EGFR+ tumors (GBM/CRC/HNSCC/NSCLC/others) refractory to prior therapies (≤3 cytotoxic lines), measurable disease, and ≥12-week life expectancy, excluding those with uncontrolled CNS metastases, cardiac dysfunction (NYHA III-IV/EF<40%), active infections (CTCAE≥G3), recent major surgery (21 days), or significant effusions/keratitis. Washout periods apply for prior therapies (21 days for most, 5 half-lives for targeted agents).
Click to Show/Hide
|
||||
| Administration Dosage |
ABBV-321 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached and a recommended Phase 2 dose is determined.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03234712 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) | ||||
| Primary Endpoint |
The primary pharmacokinetic endpoints evaluate ABBV-321 exposure (AUCt, AUC), peak concentration (Cmax), time to peak (Tmax), elimination characteristics (beta, t1/2) over 78 days, along with dose-escalation outcomes (MTD, RPTD) during the first 28-day cycle in EGFR-overexpressing solid tumor patients.
|
||||
| Other Endpoint |
Secondary efficacy measures assess long-term outcomes (PFS, DOR, DCR, TTP, OS up to 5 years) using RECIST 1.1/RANO criteria, QTcF interval changes through 61 days, and ORR in both solid tumors and glioblastoma populations.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Partial Response (PR) | 4.17% | High EGFR expression (EGFR+++) | ||
| Patients Enrolled |
Advanced, histologically confirmed solid tumors associated with EGFR overexpression (centralized testing).
|
||||
| Administration Dosage |
Ser-T intravenously once every 4 weeks (Q4W; 5-50 ug/kg) in the dose-escalation phase.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03234712 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 study evaluating the safety, pharmacokinetics, and anti-tumor activity of ABBV-321 in subjects with advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR). | ||||
| Primary Endpoint |
One patient was PR (N=1/24, 4.17%), 6 patients was SD (N=6/24,25.00%). Median DOR (CR + PR + SD)=6.40 months (95% CI 3.0not reached). The median PFS=1.8 months (95% CI 1.3-5.8), median OS=7.10 months (95% CI: 4.1-12.3).
|
||||
| Other Endpoint |
Ser-T RP2D regimen=25 ug/kg Q4W.
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Partial Response (PR) | 4.20% | High EGFR expression (EGFR+++) | ||
| Patients Enrolled |
Advanced, histologically confirmed solid tumors associated with EGFR overexpression (centralized testing).
|
||||
| Administration Dosage |
Ser-T intravenously once every 4 weeks (Q4W; 5-50 ug/kg) in the dose-escalation phase.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03234712 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 study evaluating the safety, pharmacokinetics, and anti-tumor activity of ABBV-321 in subjects with advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR). | ||||
| Primary Endpoint |
Responses included 1 partial response (PR), 6 stable disease (SD), 14 progressive disease (PD); 3 patients were not evaluable for response. Median duration of clinical benefit (complete response + PR + SD) was 6.40 months (95% CI: 3.00-not reached).
|
||||
| Other Endpoint |
The median PFS was 1.80 months (95% CI: 1.30-5.80) and the median OS was 7.10 months (95% CI: 4.10-12.30).
|
||||
| Experiment 4 Reporting the Activity Date of This ADC | [3] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT03234712 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 study evaluating the safety, pharmacokinetics, and anti-tumor activity of ABBV-321 in subjects with advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR). | ||||
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 34% | High EGFR expression (EGFR+++) | ||
| Method Description |
ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
|
||||
| In Vivo Model | Glioblastoma PDX model (PDX: SNO199) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 40% | Low EGFR expression (EGFR+) | ||
| Method Description |
ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
|
||||
| In Vivo Model | Glioblastoma PDX model (PDX: SNO199) | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 76% | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,demonstrated with ABBV-321 dosed at 0.15 mg/kg 2 every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing malignant mesothelioma PDX model (PDX: 1174) | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 88.57% | Moderate EGFR expression (EGFR++) | ||
| Method Description |
ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
|
||||
| In Vivo Model | Glioblastoma PDX model (PDX: SNO207) | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 90.20% | Moderate EGFR expression (EGFR++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.2 mg/kg,every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing GBM brain cancer PDX model (PDX: SNO199) | ||||
| Experiment 6 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 91.60% | Moderate EGFR expression (EGFR++) | ||
| Method Description |
ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
|
||||
| In Vivo Model | Glioblastoma PDX model (PDX: SNO207) | ||||
| Experiment 7 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 93.70% | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.2 mg/kg,every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing GBM brain cancer PDX model (PDX: SNO207) | ||||
| Experiment 8 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 93.80% | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression, administered at 0.5 mg/kg on a Q7D 6 regimen.
|
||||
| In Vivo Model | EGFR-expressing colorectal adenocarcinoma PDX model (PDX: LoVo) | ||||
| Experiment 9 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 96.40% | Moderate EGFR expression (EGFR++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.4 mg/kg,every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing GBM brain cancer PDX model (PDX: SNO207) | ||||
| Experiment 10 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97.20% | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.4 mg/kg,every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing GBM brain cancer PDX model (PDX: SNO199) | ||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 52.40% | Moderate EGFR expression (EGFR++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.0125 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 55.30% | Low EGFR expression (EGFR+) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of lung squamous cell carcinoma cell with EGFR expression,a single dose of 0.1 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 70.60% | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.025 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 73.80% | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.1 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing A-253 CDX model | ||||
| In Vitro Model | Submandibular gland squamous cell carcinoma | A-253 cells | CVCL_1060 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 81.10% | Moderate EGFR expression (EGFR++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.3 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing A-253 CDX model | ||||
| In Vitro Model | Submandibular gland squamous cell carcinoma | A-253 cells | CVCL_1060 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 82.80% | Moderate EGFR expression (EGFR++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.1 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 82.80% | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.05 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing SW48 CDX model | ||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 83.10% | Moderate EGFR expression (EGFR++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.1 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing FaDu CDX model | ||||
| In Vitro Model | Hypopharyngeal squamous cell carcinoma | FaDu cells | CVCL_1218 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 89.90% | Low EGFR expression (EGFR+) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,administered 0.4 mg/kg,at every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing HCT 116 CDX model | ||||
| In Vitro Model | Colon carcinoma | HCT 116 cells | CVCL_0291 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 89.90% | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.1 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing HCT 116 CDX model | ||||
| In Vitro Model | Colon carcinoma | HCT 116 cells | CVCL_0291 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 91.80% | Negative EGFR expression (EGFR-) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of head and neck cancer cell with EGFR expression,a single dose of 0.3 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing FaDu CDX model | ||||
| In Vitro Model | Hypopharyngeal squamous cell carcinoma | FaDu cells | CVCL_1218 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100% | High EGFR expression (EGFR+++) | ||
| Method Description |
ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
|
||||
| In Vivo Model | Glioblastoma U-87MG CDX model | ||||
| In Vitro Model | Glioblastoma | U-87MG ATCC cells | CVCL_0022 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100% | Low EGFR expression (EGFR+) | ||
| Method Description |
ABBV-321 induces efficient tumor cell killing in cell line-derived models of SNO199 and U87NG cells with mAb806 expression with high expression.
|
||||
| In Vivo Model | Glioblastoma U-87MG CDX model | ||||
| In Vitro Model | Glioblastoma | U-87MG ATCC cells | CVCL_0022 | ||
| Experiment 14 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100% | Low EGFR expression (EGFR+) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of lung squamous cell carcinoma cell with EGFR expression,a single dose of 0.3 mg/kg.
|
||||
| In Vivo Model | EGFR-expressing EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
| Experiment 15 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100% | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.4 mg/kg,every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing U-87MG CDX model | ||||
| In Vitro Model | Glioblastoma | U-87MG ATCC cells | CVCL_0022 | ||
| Experiment 16 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100% | High EGFR expression (EGFR+++) | ||
| Method Description |
Serclutamab talirine induces efficient tumor cell killing in PDX models of brain cancer cell with EGFR expression,dosed 0.2 mg/kg,every seven days 3.
|
||||
| In Vivo Model | EGFR-expressing U-87MG CDX model | ||||
| In Vitro Model | Glioblastoma | U-87MG ATCC cells | CVCL_0022 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
15 pM
|
|||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | SW48 cells | CVCL_1724 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.23 nM | Negative EGFR expression (EGFR-) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | U-87 MGvIII cells | CVCL_0022 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.7 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | LoVo cells | CVCL_0399 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.7 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Astrocytoma | U-251MG cells | CVCL_0021 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1 nM | Moderate EGFR expression (EGFR++; IHC 2+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | LS174T cells | CVCL_1384 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.1 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | SK-CO-1 cells | CVCL_0626 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.4 nM | Negative EGFR expression (EGFR-) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Astrocytoma | SF268 cells | CVCL_1689 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.5 nM | Moderate EGFR expression (EGFR++) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
| Experiment 9 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.5 nM | Low EGFR expression (EGFR+; IHC 1+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | M059K cells | CVCL_0401 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.8 nM | Moderate EGFR expression (EGFR++; IHC 2+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | SW403 cells | CVCL_0545 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.9 nM | High EGFR expression (EGFR+++) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Primitive neuroectodermal tumor | PFSK-1 cells | CVCL_1642 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.5 nM | High EGFR expression (EGFR+++) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Gliosarcoma | SF539 cells | CVCL_1691 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.6 nM | Moderate EGFR expression (EGFR++) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | COLO 201 cells | CVCL_1987 | ||
| Experiment 14 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.8 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | M059J cells | CVCL_0400 | ||
| Experiment 15 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 3.3 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | COLO 205 cells | CVCL_0218 | ||
| Experiment 16 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 3.7 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Astrocytoma | SNB-19 cells | CVCL_0535 | ||
| Experiment 17 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.3 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | SW620 cells | CVCL_0547 | ||
| Experiment 18 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.6 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | SW1116 cells | CVCL_0544 | ||
| Experiment 19 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.6 nM | Low EGFR expression (EGFR+; IHC 1+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | U-87MG cells | CVCL_0022 | ||
| Experiment 20 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.7 nM | Low EGFR expression (EGFR+; IHC 1+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon carcinoma | RKO cells | CVCL_0504 | ||
| Experiment 21 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.8 nM | Moderate EGFR expression (EGFR++) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Rectal adenocarcinoma | SW1463 cells | CVCL_1718 | ||
| Experiment 22 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.8 nM | Negative EGFR expression (EGFR-) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Anaplastic astrocytoma | CHLA-03-AA cells | CVCL_U616 | ||
| Experiment 23 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 5.5 nM | Moderate EGFR expression (EGFR++) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | WiDr cells | CVCL_2760 | ||
| Experiment 24 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 8 nM | Moderate EGFR expression (EGFR++; IHC 2+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | SW480 cells | CVCL_0546 | ||
| Experiment 25 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 8.4 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | LN-18 cells | CVCL_0392 | ||
| Experiment 26 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 9 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | DLD-1 cells | CVCL_0248 | ||
| Experiment 27 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 9.5 nM | Moderate EGFR expression (EGFR++; IHC 2+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Cecum adenocarcinoma | LS1034 cells | CVCL_1382 | ||
| Experiment 28 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 10.6 nM | Negative EGFR expression (EGFR-) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | SNB-75 cells | CVCL_1706 | ||
| Experiment 29 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 11.8 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | T84 cells | CVCL_0555 | ||
| Experiment 30 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 12 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon carcinoma | HCT 116 cells | CVCL_0291 | ||
| Experiment 31 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 13.9 nM | Low EGFR expression (EGFR+; IHC 1+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | Caco-2 cells | CVCL_0025 | ||
| Experiment 32 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 14.5 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | T98G cells | CVCL_0556 | ||
| Experiment 33 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 16.1 nM | Low EGFR expression (EGFR+; IHC 1+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Astrocytoma | U-138MG cells | CVCL_0020 | ||
| Experiment 34 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 17.6 nM | Low EGFR expression (EGFR+; IHC 1+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | COLO 320DM cells | CVCL_0219 | ||
| Experiment 35 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 18 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Anaplastic astrocytoma | DBTRG-05MG cells | CVCL_1169 | ||
| Experiment 36 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
23.2 nM
|
|||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Glioblastoma | A-172 cells | CVCL_0131 | ||
| Experiment 37 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 24.9 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | COLO 320HSR cells | CVCL_0220 | ||
| Experiment 38 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 28.4 nM | High EGFR expression (EGFR+++; IHC 3+) | ||
| Method Description |
The inhibitory activity of serclutamab talirine against cancer cell growth was compared with ABBV-221 against various human cancer cell lines in vitro. The cells were treated with serclutamab talirine and ABBV-221.
|
||||
| In Vitro Model | Colon adenocarcinoma | HCT 15 cells | CVCL_0292 | ||
References